How Does H. pylori Affect Stomach Acid?

← Back to Clinical Articles

Article: How Does H. pylori Affect Stomach Acid?  |  Category: Gut  |  Authored by: Brian Lamkin, DO

The Most Common Infection Nobody Talks About

Helicobacter pylori infects over half the global population. In the United States, prevalence ranges from 20 to 50 percent depending on age, ethnicity, and socioeconomic factors. Most infected individuals are unaware of the infection because it often produces no acute symptoms. The infection is acquired in childhood, usually through oral-oral or fecal-oral transmission within families, and persists for life if untreated. The clinical significance extends far beyond ulcers. Chronic H. pylori infection progressively alters gastric acid production, damages the gastric mucosa, impairs nutrient absorption, and creates downstream conditions that affect multiple organ systems.

The Urease Survival Strategy

The stomach maintains a pH of 1.5 to 3.5, one of the most hostile environments in the human body. Most bacteria cannot survive this acidity. H. pylori's primary survival mechanism is the enzyme urease^[1]. Urease catalyzes the hydrolysis of urea (present in gastric secretions) into ammonia (NH3) and carbon dioxide (CO2). Ammonia is a strong base that neutralizes hydrochloric acid in the immediate vicinity of the bacterium. This creates a protective alkaline microenvironment, a pH bubble surrounding each organism, that allows H. pylori to survive and multiply within the mucus layer overlying the gastric epithelium. The urease reaction is so central to H. pylori's survival that urease-negative strains cannot colonize the stomach. This is also the basis of the urea breath test: the patient ingests labeled urea, H. pylori's urease cleaves it, and the labeled carbon dioxide is detected in exhaled breath.

From Colonization to Inflammation

Once established in the mucus layer, H. pylori produces a chronic inflammatory response. The bacterium adheres to gastric epithelial cells using adhesins (BabA, SabA, OipA) and injects virulence factors (CagA, VacA) directly into host cells through a type IV secretion system. CagA disrupts intracellular signaling pathways, promotes cell proliferation, and stimulates cytokine release. VacA produces vacuolation (damage) in epithelial cells and impairs T-cell function. The immune system responds with neutrophil and lymphocyte infiltration of the gastric mucosa, producing active chronic gastritis. Importantly, the immune response is never sufficient to clear the infection. H. pylori has evolved mechanisms to evade immune clearance, producing a state of perpetual inflammation that progressively damages the gastric mucosa over years to decades.

Antral vs Corpus Predominant Infection

The clinical effect of H. pylori on acid production depends on where in the stomach the infection predominates. Antral-predominant infection (lower stomach) damages somatostatin-producing D cells. Somatostatin normally inhibits gastrin release. When D cells are destroyed, gastrin production is unopposed, driving increased acid output from the parietal cells in the body (corpus) of the stomach. This hyperacidic state produces duodenal ulcers and acid reflux symptoms. Corpus-predominant infection directly damages parietal cells (the acid-producing cells in the body of the stomach), progressively reducing acid output. This produces hypochlorhydria and eventually achlorhydria (complete absence of acid production). Corpus-predominant infection is associated with gastric ulcers, gastric atrophy, intestinal metaplasia, and significantly increased gastric cancer risk. Many patients transition from antral-predominant to corpus-predominant infection over decades, shifting from excess acid to insufficient acid production.

The Progression to Hypochlorhydria

Chronic corpus gastritis from H. pylori produces a progressive sequence called the Correa cascade: normal mucosa to chronic gastritis to atrophic gastritis (loss of parietal cells) to intestinal metaplasia (replacement of gastric epithelium with intestinal-type cells) to dysplasia to gastric cancer. Not all patients progress through the full cascade, but the direction is consistent: chronic inflammation damages parietal cells, reduces acid output, and progressively impairs the gastric environment. The clinical consequence of this progression is hypochlorhydria: insufficient acid to perform the normal functions of gastric acid, which include protein digestion (pepsin activation requires pH below 3), sterilization of ingested bacteria, conversion of minerals to absorbable form, and stimulation of pancreatic enzyme and bile release.

The H. pylori to SIBO Connection

Gastric acid is the primary barrier preventing oral and ingested bacteria from reaching the small intestine. When H. pylori reduces acid output sufficiently, bacteria that would normally be killed in the stomach survive passage and can establish small intestinal bacterial overgrowth (SIBO)^[2]. Studies have demonstrated significantly higher rates of SIBO in H. pylori-positive patients compared to uninfected controls. This connection is critical for patients with recurrent SIBO: if the root cause is H. pylori-driven hypochlorhydria, the SIBO will relapse after every antimicrobial treatment because the acid barrier remains compromised. Eradicating H. pylori and restoring acid production addresses the upstream cause and reduces SIBO recurrence.

Iron Deficiency: The Most Common Nutrient Consequence

H. pylori is one of the most under-recognized causes of iron deficiency anemia^[3]. The mechanism operates through three pathways. First, gastric acid is required to convert dietary ferric iron (Fe3+) to ferrous iron (Fe2+), the form that is absorbed. Hypochlorhydria from H. pylori impairs this conversion, reducing iron absorption regardless of dietary intake or supplementation. Second, H. pylori itself consumes iron as a growth factor, directly competing with the host for available iron. Third, chronic gastric inflammation produces hepcidin elevation, which sequesters iron in macrophages and further reduces absorption. The clinical presentation: a patient with persistently low ferritin despite adequate dietary iron intake and oral supplementation who does not respond to iron therapy until H. pylori is eradicated. This is one of the most common scenarios in our practice.

B12 and Other Nutrient Consequences

Vitamin B12 absorption requires a multi-step process that begins with gastric acid and pepsin releasing B12 from food proteins. In the stomach, free B12 binds to R-protein (haptocorrin), then in the duodenum, pancreatic enzymes release B12 from R-protein, and B12 binds to intrinsic factor (produced by parietal cells) for absorption in the terminal ileum. H. pylori impairs this process at multiple points: hypochlorhydria reduces the initial B12 release from food, atrophic gastritis reduces intrinsic factor production (because intrinsic factor is produced by the same parietal cells that produce acid), and the inflammatory milieu may directly impair B12 binding to intrinsic factor. Calcium absorption is similarly impaired because acid-dependent calcium dissolution is reduced. Magnesium, zinc, and folate absorption are also compromised in chronic hypochlorhydria.

The PPI Paradox

Proton pump inhibitors (PPIs) are among the most prescribed medications worldwide and are frequently used for H. pylori-associated symptoms (reflux, gastritis, ulcers). PPIs suppress acid production by irreversibly blocking the hydrogen-potassium ATPase in parietal cells. While PPIs provide symptom relief, they compound the hypochlorhydria that H. pylori is already producing, accelerate the progression to atrophic gastritis (particularly in H. pylori-positive patients), further impair nutrient absorption (iron, B12, calcium, magnesium), and remove the acid barrier that protects against SIBO. Long-term PPI use in H. pylori-positive patients without eradication accelerates the very cascade (atrophy, metaplasia) that H. pylori is driving. This is why H. pylori testing should precede long-term PPI therapy, and why eradication should be attempted before committing to chronic acid suppression.

Thyroid and Autoimmune Connections

H. pylori infection has been associated with autoimmune conditions, particularly autoimmune thyroid disease. The proposed mechanisms include molecular mimicry (H. pylori CagA antigen shares structural similarity with thyroid peroxidase), chronic immune activation from persistent infection driving bystander autoimmune responses, and the systemic inflammatory state produced by chronic gastric inflammation elevating hs-CRP and inflammatory cytokines that interfere with thyroid hormone conversion. In patients with Hashimoto's thyroiditis and concurrent H. pylori, some studies have demonstrated reduction in thyroid antibody titers after H. pylori eradication. The clinical implication: H. pylori testing should be part of the workup for autoimmune thyroid disease, and eradication may contribute to reducing the autoimmune driver.

Testing for H. pylori

The urea breath test (UBT) is the most accurate non-invasive test for active H. pylori infection^[4]. The patient ingests labeled urea, H. pylori urease cleaves it, and labeled CO2 is measured in exhaled breath. Sensitivity and specificity exceed 95 percent. Important: PPIs must be discontinued for at least 2 weeks before testing (PPIs suppress H. pylori without eradicating it, producing false-negative results). Antibiotics and bismuth must be discontinued for at least 4 weeks. Stool antigen testing is an alternative non-invasive option with similar accuracy. Serology (IgG antibodies) detects exposure but cannot distinguish active from past infection, making it less useful for clinical decision-making. Histology from endoscopic biopsy is the gold standard but requires invasive procedure. For most clinical purposes, the urea breath test or stool antigen is sufficient.

Eradication: The Treatment Approach

Standard eradication therapy is triple therapy (PPI plus clarithromycin plus amoxicillin or metronidazole) or bismuth quadruple therapy (PPI plus bismuth subsalicylate plus tetracycline plus metronidazole) for 14 days. Eradication rates with standard triple therapy have declined to 70 to 80 percent in many regions due to increasing clarithromycin resistance, making quadruple therapy or susceptibility-guided therapy increasingly preferred. Functional medicine adjuncts include mastic gum (Pistacia lentiscus resin, which has demonstrated anti-H. pylori activity in vitro), Saccharomyces boulardii (reduces antibiotic side effects and may improve eradication rates), biofilm-disrupting agents (NAC), and probiotics during and after eradication to reduce dysbiosis from the antibiotic course. Post-eradication confirmation by repeat UBT or stool antigen testing at minimum 4 weeks after completing treatment is essential. Approximately 15 to 20 percent of patients require a second eradication attempt.

After Eradication: Acid Restoration

Successful H. pylori eradication does not immediately restore normal acid production. Parietal cell recovery takes weeks to months, and patients with significant atrophic gastritis may have permanent reduction in acid output. During the recovery period, temporary HCl supplementation (betaine HCl with pepsin, titrated to tolerance) may be used to support digestion, mineral absorption, and SIBO prevention while the mucosa recovers. Nutrient repletion (iron, B12, vitamin D, magnesium, zinc) should be aggressive during the post-eradication period to replenish stores that were depleted during the infection. Fasting insulin and metabolic markers should be reassessed as the inflammatory burden from chronic infection resolves, since H. pylori-driven inflammation can contribute to insulin resistance that improves with eradication.

The Lamkin Clinic Approach

H. pylori evaluation at The Lamkin Clinic is part of the comprehensive gut assessment for any patient presenting with unexplained iron deficiency, recurrent SIBO, persistent dyspepsia, autoimmune thyroid disease, or unexplained B12 deficiency. Testing uses urea breath test or stool antigen (after appropriate PPI washout). When positive, eradication is pursued with evidence-based antibiotic therapy plus functional adjuncts (mastic gum, S. boulardii, NAC). Lab evaluation includes ferritin and iron studies, hs-CRP, Free T3 and thyroid panel, vitamin D, and fasting insulin. Post-eradication confirmation, acid restoration, nutrient repletion, and SIBO evaluation complete the protocol. The goal is not just eradicating the organism. The goal is restoring the physiological cascade that the infection disrupted.

The Lamkin Clinic, Edmond Oklahoma | lamkinclinic.com

Frequently Asked Questions

Related Conditions

Related Clinical Articles

References and Further Reading

1. [1]Mobley HLT. Urease. In: Mobley HLT, Mendz GL, Hazell SL, eds. Helicobacter pylori: Physiology and Genetics. ASM Press; 2001.
2. [2]Lombardo L, et al. Increased incidence of small intestinal bacterial overgrowth during proton pump inhibitor therapy. Clin Gastroenterol Hepatol. 2010;8(6):504-508.
3. [3]Muhsen K, Cohen D. Helicobacter pylori infection and iron stores: a systematic review and meta-analysis. Helicobacter. 2008;13(5):323-340.
4. [4]Chey WD, et al. ACG clinical guideline: treatment of Helicobacter pylori infection. Am J Gastroenterol. 2017;112(2):212-239.